Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study.
Autorzy:
Yao J; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, CA 90024, USA.; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA. Hagiwara A; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, CA 90024, USA.; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA. Oughourlian TC; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, CA 90024, USA.; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA.; Neuroscience Interdepartmental Program, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA. Wang C; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, CA 90024, USA.; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA. Raymond C; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, CA 90024, USA.; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA. PopeWB; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA. Salamon N; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA. Lai A; UCLA Neuro-Oncology Program, University of California, Los Angeles, CA 90024, USA.; Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA. Ji M; UCLA Neuro-Oncology Program, University of California, Los Angeles, CA 90024, USA.; Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA. Nghiemphu PL; UCLA Neuro-Oncology Program, University of California, Los Angeles, CA 90024, USA.; Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA. Liau LM; Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA. Cloughesy TF; UCLA Neuro-Oncology Program, University of California, Los Angeles, CA 90024, USA.; Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA. Ellingson BM; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, CA 90024, USA.; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA.; UCLA Neuro-Oncology Program, University of California, Los Angeles, CA 90024, USA.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2022 May 20; Vol. 14 (10). Date of Electronic Publication: 2022 May 20.
Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI.
Autorzy:
Hagiwara A; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, 924 Westwood Blvd., Suite 615, Los Angeles, CA, 90024, USA.; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.; Department of Radiology, Juntendo University School of Medicine, Tokyo, Japan. Tatekawa H; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, 924 Westwood Blvd., Suite 615, Los Angeles, CA, 90024, USA.; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.; Department of Diagnostic and Interventional Radiology, Osaka City University Graduate School of Medicine, Osaka, Japan. Yao J; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, 924 Westwood Blvd., Suite 615, Los Angeles, CA, 90024, USA.; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.; Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California Los Angeles, Los Angeles, CA, USA. Raymond C; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, 924 Westwood Blvd., Suite 615, Los Angeles, CA, 90024, USA.; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Everson R; Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Patel K; Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Mareninov S; Department of Pathology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Yong WH; Department of Pathology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Salamon N; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. PopeWB; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Nghiemphu PL; UCLA Neuro-Oncology Program, University of California, Los Angeles, Los Angeles, CA, USA.; Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Liau LM; Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Cloughesy TF; UCLA Neuro-Oncology Program, University of California, Los Angeles, Los Angeles, CA, USA.; Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Ellingson BM; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, 924 Westwood Blvd., Suite 615, Los Angeles, CA, 90024, USA. .; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. .; Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California Los Angeles, Los Angeles, CA, USA. .; UCLA Neuro-Oncology Program, University of California, Los Angeles, Los Angeles, CA, USA. .; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Jan 20; Vol. 12 (1), pp. 1078. Date of Electronic Publication: 2022 Jan 20.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma.
Autorzy:
Patel KS; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers (CVIB), Dept. of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, 924 Westwood Blvd, Suite 615, Los Angeles, CA, 90024, USA.; Dept. of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Yao J; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers (CVIB), Dept. of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, 924 Westwood Blvd, Suite 615, Los Angeles, CA, 90024, USA.; Dept. of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.; UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Raymond C; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers (CVIB), Dept. of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, 924 Westwood Blvd, Suite 615, Los Angeles, CA, 90024, USA.; Dept. of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Yong W; Dept. of Pathology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Everson R; Dept. of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Liau LM; Dept. of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Nathanson D; Dept. of Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Kornblum H; Dept. of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Wang C; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers (CVIB), Dept. of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, 924 Westwood Blvd, Suite 615, Los Angeles, CA, 90024, USA.; Dept. of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Oughourlian T; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers (CVIB), Dept. of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, 924 Westwood Blvd, Suite 615, Los Angeles, CA, 90024, USA.; Dept. of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.; Neuroscience Interdisciplinary Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Lai A; UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.; Dept. of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Nghiemphu PL; UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.; Dept. of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. PopeWB; Dept. of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Cloughesy TF; UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.; Dept. of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Ellingson BM; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers (CVIB), Dept. of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, 924 Westwood Blvd, Suite 615, Los Angeles, CA, 90024, USA. .; Dept. of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. .; Dept. of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2020 Sep 09; Vol. 10 (1), pp. 14819. Date of Electronic Publication: 2020 Sep 09.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study.
Autorzy:
Yao J; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, 924 Westwood Blvd., Suite 615, Los Angeles, CA, 90024, USA.; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.; Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California, Los Angeles, Los Angeles, CA, USA. Hagiwara A; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, 924 Westwood Blvd., Suite 615, Los Angeles, CA, 90024, USA.; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Raymond C; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, 924 Westwood Blvd., Suite 615, Los Angeles, CA, 90024, USA.; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Shabani S; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, 924 Westwood Blvd., Suite 615, Los Angeles, CA, 90024, USA. PopeWB; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Salamon N; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Lai A; UCLA Neuro-Oncology Program, University of California, Los Angeles, Los Angeles, CA, USA.; Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Ji M; UCLA Neuro-Oncology Program, University of California, Los Angeles, Los Angeles, CA, USA.; Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Nghiemphu PL; UCLA Neuro-Oncology Program, University of California, Los Angeles, Los Angeles, CA, USA.; Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Liau LM; Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Cloughesy TF; UCLA Neuro-Oncology Program, University of California, Los Angeles, Los Angeles, CA, USA.; Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Ellingson BM; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, 924 Westwood Blvd., Suite 615, Los Angeles, CA, 90024, USA. .; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. .; Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California, Los Angeles, Los Angeles, CA, USA. .; UCLA Neuro-Oncology Program, University of California, Los Angeles, Los Angeles, CA, USA. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2020 Jul 17; Vol. 10 (1), pp. 11922. Date of Electronic Publication: 2020 Jul 17.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry.
Autorzy:
Chakhoyan A; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Yao J; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.; Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California Los Angeles, Los Angeles, CA, USA. Leu K; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. PopeWB; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Salamon N; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Yong W; Division of Neuropathology, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Lai A; Department of Neurology, Ronald Reagan UCLA Medical Center, University of California Los Angeles, Los Angeles, CA, USA. Nghiemphu PL; Department of Neurology, Ronald Reagan UCLA Medical Center, University of California Los Angeles, Los Angeles, CA, USA. Everson RG; Department of Neurosurgery, Ronald Reagan UCLA Medical Center, University of California Los Angeles, Los Angeles, CA, USA. Prins RM; Department of Neurosurgery, Ronald Reagan UCLA Medical Center, University of California Los Angeles, Los Angeles, CA, USA. Liau LM; Department of Neurosurgery, Ronald Reagan UCLA Medical Center, University of California Los Angeles, Los Angeles, CA, USA. Nathanson DA; Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, CA, USA. Cloughesy TF; Department of Neurology, Ronald Reagan UCLA Medical Center, University of California Los Angeles, Los Angeles, CA, USA. Ellingson BM; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. .; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. .; Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California Los Angeles, Los Angeles, CA, USA. .; UCLA Neuro Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2019 Feb 26; Vol. 9 (1), pp. 2846. Date of Electronic Publication: 2019 Feb 26.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Magaki S; Section of Neuropathology, Department of Pathology and Laboratory Medicine. Chang E; Department of Neurology. Hammond RR; Division of Neuropathology, Department of Pathology. Yang I; Department of Neurosurgery. Mackenzie IR; Department of Pathology, University of British Columbia and Vancouver General Hospital, Vancouver, British Columbia, Canada. Chou BT; Division of Rheumatology, Department of Medicine. Choi SI; Division of Rheumatology, Department of Medicine. Jen JC; Department of Neurology. PopeWB; Department of Radiological Sciences. Bell DA; Department of Medicine, Western University, London, Ontario, Canada. Vinters HV; Section of Neuropathology, Department of Pathology and Laboratory Medicine.; Department of Neurology.; Brain Research Institute, University of California, Los Angeles (UCLA) Medical Center and David Geffen School of Medicine, Los Angeles, California, USA.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
